Cedar Brook Corporate Center
Bruce Simon
4A Cedar Brook Drive
Cranbury, NJ 08512
Office: (609) 655.5400
Email: bsimon@easternproperties.net

Top Science & Biotech Lab Headlines – Fall 2014

Share on Facebook0Tweet about this on TwitterShare on LinkedIn0Share on Google+0

Latest science & biotech headlines summarized for Cedar Brook tenants and leaders in the industry.  Topics of interest include drug trial regulation, anticipated amendments to FDA legislation, immigration plans that may affect the industry and more.  Read the summary of our top picks for what might affect you directly as an entity that rents or owns laboratory facilities.

Should The FDA Force Drug Makers To Discuss Their Clinical Trials? (Dec 1st)
The Journal of the American Medical Association (JAMA) published a recent article calling for mandatory submission of drug trial designs by biopharmaceutical companies to the FDA for approval.  Currently any company can submit a request, known as a special protocol assessment (SPA), to the FDA to receive feedback on their trial design, however it is not mandatory for drug testing.  Read more >>>

Center Stage: High Rollers of Science & Technology Honored at 2014 R&D 100 Awards (Dec 1st)
R&D Magazine recently hosted their annual R&D 100 Awards event. This event highlights companies on the forefront of high-tech innovation and after 50+ years in the running, this event has gained itself the nickname “Oscars of Invention”.  Read more >>>

Science gets a nod in Obama’s immigration plans (Nov 21st)
Obama announced in a recent immigration speech policies he is endorsing to make it easier for highly skilled foreign immigrants and recent science graduates to get permits to work in the US despite legislation that is currently held up in the House of Representatives.  Read more >>>

U.S. Proposes Greater Public Access to Data from Clinical Trials (Nov 20th)
Both the National Institute of Health (NIH) and the Department of Health & Human Resources are arguing for new legislation that would require even failed trials to publish results to prevent future duplication of trials.  Read more >>>

Incoming GOP Senate Will Likely Press FDA To Ease Up On Regulation (Nov 10th)
With the recently elected Republican majority Senate, strategist predict the GOP will likely try to challenge the FDA to ease up regulation on drug and device manufacturers which they argue has overly burdened the industry in getting new drugs & products approved and on the market.  Read more >>>

Leave a Reply

Your email address will not be published. Required fields are marked *